Compare VRCA & ATLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | ATLX |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 149.7M |
| IPO Year | 2018 | 2012 |
| Metric | VRCA | ATLX |
|---|---|---|
| Price | $6.15 | $4.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $17.00 | $12.00 |
| AVG Volume (30 Days) | 83.8K | ★ 993.6K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,577,000.00 | $92,491.00 |
| Revenue This Year | N/A | $64,564.67 |
| Revenue Next Year | $94.44 | $785.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.49 | $3.60 |
| 52 Week High | $9.82 | $8.25 |
| Indicator | VRCA | ATLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 38.75 |
| Support Level | $5.13 | $4.14 |
| Resistance Level | $6.40 | $5.21 |
| Average True Range (ATR) | 0.73 | 0.48 |
| MACD | -0.20 | -0.16 |
| Stochastic Oscillator | 21.52 | 4.90 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.